Metformin use doesn't cut incidence of bladder cancer

February 11, 2014
Metformin use doesn't cut incidence of bladder cancer

(HealthDay)—For patients with type 2 diabetes, metformin use is not associated with a significantly reduced risk of bladder cancer, according to a study published online Feb. 4 in Diabetes Care.

Ronac Mamtani, M.D., from the University of Pennsylvania in Philadelphia, and colleagues conducted a involving 87,600 patients with in The Health Improvement Network database. The incidence of in new users of and sulfonylureas was examined. Metformin or sulfonylurea use was treated as a time-dependent variable. The authors hoped to address the time-related biases that may have affected previous studies relating to the effect of metformin on cancer risk.

The researchers identified 196 incident bladder cancers in the metformin cohort and 66 in the sulfonylurea cohort. The risk of bladder cancer was not significantly decreased in association with metformin use (hazard ratio, 0.81; 95 percent confidence interval [CI], 0.60 to 1.09). The correlation was not affected by sex (P for interaction = 0.20). There was also no reduction in bladder cancer risk with increased duration of metformin use relative to use of sulfonylureas (three to less than four years of use: 0.57 [95 percent CI, 0.25 to 1.34]; four to less than five years of use: 0.93 [95 percent CI, 0.30 to 2.85]; and five or more years of use: 1.18 [95 percent CI, 0.44 to 3.19]; P for trend = 0.26).

"Similar methods should be used to study other cancers that have previously been identified as potentially preventable with metformin," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Post-breast cancer, metformin has no effect on mortality

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Post-breast cancer, metformin has no effect on mortality

July 3, 2013
(HealthDay)—For older women with diabetes and breast cancer, there is no association between metformin use and all-cause or breast cancer-specific mortality, according to a study published online April 30 in Diabetes Care.

Sulfonylureas up cardio events versus metformin

November 7, 2012
(HealthDay)—Use of sulfonylureas for initial treatment of diabetes is associated with increased cardiovascular events and death compared with metformin, according to a study published in the Nov. 6 issue of the Annals of ...

Metformin may increase risk of cognitive impairment

September 21, 2013
(HealthDay)—Metformin may increase the risk of cognitive impairment in patients with diabetes; however, calcium supplementation may attenuate this risk, according to research published online Sept. 5 in Diabetes Care.

Cumulative metformin linked to mortality post-prostate cancer

August 8, 2013
(HealthDay)—Among elderly men with diabetes, increased cumulative duration of metformin following a prostate cancer (PC) diagnosis correlates with decreased all-cause and PC-specific mortality, according to a study published ...

Lung cancer risk unaffected by metformin use in diabetes

August 30, 2012
(HealthDay)—Patients with type 2 diabetes who take metformin do not have a reduced risk of lung cancer, in contrast to previous observational studies, according to a study published online Aug. 24 in Diabetes Care.

Detection bias may explain raised bladder CA risk in T2DM

September 17, 2013
(HealthDay)—Early detection bias may explain the pattern of increased bladder cancer risk previously reported in patients with type 2 diabetes, according to a study published online Aug. 29 in Diabetes Care.

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.